Risk of employee infection and production stoppages due to COVID-19
First written in FY2020. 9 of 13 entries say "Restated". Latest entry: FY2024.
The whole theme swung hardest in 2025: 2 of 12 companies on the "Worse" side.
8 other companies' latest entry also says "Dropped".
- FY2024DroppedAnnual report
「As social and economic activity continued to normalise following the COVID-19 pandemic, the economy entered a gradual recovery trend.」
The specific risk of production stoppages due to employee infections was not included in the current year's risk list, and the business environment was described as continuing to normalise following the COVID-19 pandemic. - FY2024-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, there were no material changes in the occurrence of major risks that management recognizes could materially affect the financial position, operating performance or cash flows of the consolidated companies, among the matters concerning the business and accounting conditions described in the quarterly report, or in the business and other risks described in the annual securities report for the previous fiscal year.」
No significant changes were indicated during the quarter regarding the risk of employee infections and production stoppages due to COVID-19. - FY2024-Q1RestatedAnnual report
「During the three-month period ended 30 June, there were no new risks that management recognizes as having the potential to materially affect the financial position, operating results or cash flows of the consolidated companies, and no material changes to the business risks described in the annual securities report for the previous fiscal year.」
No significant changes were indicated during the quarter regarding the risk of employee infections and production stoppages due to COVID-19. - FY2023RestatedAnnual report
「As of the date of submission of the annual securities report, the company expects the impact of COVID-19 to remain limited and believes that it will not have a significant impact on future cash management.」
The company continues to recognise the impact of the infectious disease as limited and states that no significant impact on cash management is expected. - FY2022RestatedAnnual report
「As measures against infectious diseases affecting employees and others, the Group is taking company-wide steps to prevent outbreaks of COVID-19 and other infectious diseases, including health checks for all employees, encouraging handwashing and alcohol disinfection, ensuring mask wearing, recommending staggered working hours and telework, and conducting meetings online instead of holding in-person meetings and business trips.」
The company continues to address the risks of employee infections and production stoppages, as well as measures including health checks, disinfection, mask wearing, staggered working hours, telework and online meetings. - FY2022-Q3RestatedAnnual report
「Regarding the impact of COVID-19, the company and its domestic subsidiaries have continued business activities with stringent measures in place, and have maintained operating rates at the same level as under normal conditions even after the end of the nine-month period of the third quarter of the current consolidated fiscal year.」
The company has continued domestic business activities with infectious-disease measures in place and has maintained operating rates at the same level as under normal conditions after the end of the cumulative quarterly period. - FY2022-Q2RestatedAnnual report
「Regarding the impact of COVID-19, the company and its domestic subsidiaries have continued business activities with stringent measures in place, and have maintained operating rates at the same level as under normal conditions even after the end of the six-month period of the second quarter of the current consolidated fiscal year.」
The company has continued domestic business activities with infectious-disease measures in place and has maintained operating rates at the same level as under normal conditions after the end of the cumulative quarterly period. - FY2022-Q1RestatedAnnual report
「Regarding the impact of COVID-19, the company and its domestic subsidiaries have continued business activities with stringent measures in place, and have maintained operating rates at the same level as under normal conditions even after the end of the three-month period of the first quarter of the current consolidated fiscal year.」
The company has continued domestic business activities with infectious-disease measures in place and has maintained operating rates at the same level as under normal conditions after the end of the cumulative quarterly period. - FY2021RestatedAnnual report
「As measures against infectious diseases affecting employees and others, the Group is taking company-wide steps to prevent outbreaks of COVID-19 and other infectious diseases, including health checks for all employees, encouraging handwashing and alcohol disinfection, ensuring mask wearing, recommending staggered working hours and telework, and in principle prohibiting meetings and business travel.」
The company continues to recognise the risk of production stoppages caused by employee infections and continues measures including health checks, disinfection, mask wearing and telework. - FY2021-Q3RestatedAnnual report
「Regarding the impact of COVID-19, the company and its domestic subsidiaries have continued business activities with stringent measures in place, and have maintained operating rates at the same level as under normal conditions even after the end of the nine-month period of the third quarter of the current consolidated fiscal year.」
The company has continued domestic business activities with infectious-disease measures in place and has maintained operating rates at the same level as under normal conditions after the end of the cumulative quarterly period. - FY2021-Q2MitigatedAnnual report
「Regarding the impact of COVID-19, the company and its domestic subsidiaries have continued business activities with stringent measures in place, and have maintained operating rates at the same level as under normal conditions even after the end of the six-month period of the second quarter of the current consolidated fiscal year.」
The company states that its domestic operations have continued with stringent measures in place and that operating rates have remained at the same level as under normal conditions after the end of the cumulative quarterly period. - FY2021-Q1WorsenedAnnual report
「Although the impact of COVID-19 on the company's business is expanding, the company continues to regard its impact on operating results as limited.」
The expanded impact of COVID-19 on the business is explicitly stated. At the same time, the company continues to recognise its impact on operating results as limited. - FY2020First statedAnnual report
「If employees or other personnel become infected with COVID-19 or other infectious diseases, production at factories could be suspended, potentially adversely affecting the financial position, operating results and cash flows of the Group.」
COVID-19 is explicitly identified, and the risk that employee infections could lead to factory production stoppages and other consequences is newly described.